Phase 3 Readout

ALNY: Phase 3 Topline: HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the

Name: Phase 3 Topline: HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the
Start: 2026-12-02
End: 2026-12-02

December 2, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 2, 2026
Company: ALNYLAM PHARMACEUTICALS, INC. (ALNY)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the

December 2, 2026

ALNY overview →

Company: ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Indication: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy